Multinational pharmaceutical major Merck Sharp and Dohme or MSD said that it has filed a case against domestic drug manufacturer Glenmark Pharmaceuticals in the Delhi High Court alleging patent violation of its anti-diabetes drugs Januvia and Janumet.
“We are disappointed in Glenmark’s decision to introduce products that directly infringe upon our intellectual property,” said an MSD spokesperson in an email reply. “We believe our patents for Januvia and Janumet are valid and enforceable and will vigorously defend them.”
Glenmark, which recently launched its low-cost version of the drug, has, however, maintained that its products — Zita and Zita-Met — are branded generics and were launched after due diligence.
In a reply to FE’s query, the company said, “Glenmark is a responsible company and has launched the products after due diligence and research.”
In India, there are about 60-65 million people with type 2 diabetes. Januvia and Janumet are once-daily prescription pills.